PITX2 DNA methylation was also analyzed in high-risk (N+, ER/PR+, and HER2−) breast cancer patients treated with adjuvant anthracycline-based chemotherapy, which improved clinical outcome of the patients. Here, PITX2 is linked to breast cancer.